Genentech, along with the Breast International Group, Breast European Adjuvant Study Team and Frontier Science Foundation, recently reported positive results from the Phase III Aphinity study for combining Perjeta, Herceptin and chemotherapy in treating certain breast cancer patients.
“These results from the positive APHINITY study represent an important addition to the body of data for Perjeta in the treatment of people with HER2-positive early breast cancer,” Dr. Sandra Horning, chief medical officer and head of Global Product Development, said in a statement. “We look forward to discussing these adjuvant results with global regulatory authorities.”
The study met its primary endpoint. The combination of treatments reduced the risk of recurrence of invasive disease or death in HER2-positive early breast cancer patients when compared to treatments using only Herceptin and chemotherapy. Additionally, the Perjeta-based regimen was consistent with previously shown safety profiles.
“APHINITY provides yet another example of the importance of industry-academic collaborations and their value in advancing cancer care for people affected by this challenging disease,” Dr. Gunter von Minckwitz, study coordinator from the Breast International Group and academic study partners, said.
Alerts Sign-up